Growth Metrics

Legend Biotech (LEGN) Income from Non-Controlling Interests (2020 - 2025)

Legend Biotech (LEGN) posted Income from Non-Controlling Interests of -$40.2 million for Q1 2025, up 36.63% on a QoQ basis from -$63.4 million in Q3 2024, and up 62.72% year-over-year from -$24.7 million in Q1 2024.

Legend Biotech (LEGN) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$40.2 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -13.75 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 -40.19 Mn
Sep 30, 2024 -63.42 Mn
Jun 30, 2024 -28.73 Mn
Mar 31, 2024 -107.79 Mn
Sep 30, 2023 -82.45 Mn
Jun 30, 2023 -206.10 Mn
Mar 31, 2023 -98.59 Mn
Sep 30, 2022 -89.14 Mn
Jun 30, 2022 -181.41 Mn
Mar 31, 2022 -38.78 Mn
Sep 30, 2021 -122.57 Mn
Jun 30, 2021 -92.63 Mn
Mar 31, 2021 -76.55 Mn
Sep 30, 2020 -67.13 Mn